alpidem

04/01/1993 - "The efficacy of alpidem in the treatment of panic disorder remains uncertain and requires assessment in a controlled trial."
01/01/1994 - "Paradoxical acute anxiety exacerbation with alpidem in a panic disorder patient."
04/01/1993 - "Alpidem in the treatment of panic disorder."
04/01/1993 - "The effect of alpidem was investigated in an 8-week, open, clinical trial in 13 patients with panic disorder, with or without agoraphobia. "

02/01/1989 - "Alpidem was significantly more effective than placebo in decreasing the severity of anxiety, both in the physician's judgment [total HRSA (p = 0.007), psychic symptoms (p = 0.0040), somatic symptoms (p = 0.0002)] and in the patients' evaluation [STAI x 1 (p = 0.0001) and VAS (p = 0.0003)]. "
01/01/1991 - "Half of the alpidem group had a decrease of 50 percent or greater in their HAM-A scores with an almost equal effect on psychic and somatic symptoms. "

01/01/1991 - "The most common side effects with alpidem and lorazepam were lightheadedness, drowsiness, and daytime tiredness. "
11/01/2012 - "In contrast to the anxioselective profile displayed in preclinical models, compounds such as bretazenil, TPA023, and MRK 409 produced benzodiazepine-like side effects (sedation, dizziness) in Phase I studies, whereas alpidem and ocinaplon exhibited many of the characteristics of an anxioselective in the clinic. "

10/01/2017 - "For individual studies, alpidem was superior to placebo in improving the overall schizophrenia symptoms. "

02/01/1997 - "Activity on omega 1 receptor subtypes is perhaps not sufficient in order to obtain a true anti-conflict effect and compounds such as alpidem only relieve some of the symptoms of anxiety disorders."
05/01/1990 - "On the therapeutic action of alpidem in anxiety disorders: an overview of the European data."
07/01/1994 - "Under a double-blind procedure, 122 patients suffering from general anxiety disorders were randomly allocated to either alpidem (50 mg, three times a day) or alprazolam (0.5 mg, three times a day) for six weeks, followed by a two-week placebo withdrawal phase. "
07/01/1992 - "Twenty-three psychiatric out-patients with generalised anxiety disorder received alpidem (mean dose 112.5 mg daily) or lorazepam (mean 3.5 mg daily) in doses adjusted to clinical need under double-blind conditions. "
07/01/1992 - "Alpidem and lorazepam in the treatment of patients with anxiety disorders: comparison of physiological and psychological effects."